Real‐time analysis of the cancer genome and fragmentome from plasma and urine cell‐free DNA using nanopore sequencing
EMBO Molecular Medicine · 2023
DOI: 10.15252/emmm.202217282 ↗Kurz gefasst
Fachartikel in der Zeitschrift EMBO Molecular Medicine, 2023. Verfasst von Ymke van der Pol und 16 weiteren Autor:innen. Beteiligte Einrichtung: Pathology, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Cell-Free Nucleic Acids, Nanopore Sequencing, Lung Neoplasms. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: KWF Kankerbestrijding (DCS).
Abstract (Originalsprache)
Cell‐free DNA (cfDNA) can be isolated and sequenced from blood and/or urine of cancer patients. Conventional short‐read sequencing lacks deployability and speed and can be biased for short cfDNA fragments. Here, we demonstrate that with Oxford Nanopore Technologies (ONT) sequencing we can achieve delivery of genomic and fragmentomic data from liquid biopsies. Copy number aberrations and cfDNA fragmentation patterns can be determined in less than 24 h from sample collection. The tumor‐derived cfDNA fraction calculated from plasma of lung cancer patients and urine of bladder cancer patients was highly correlated ( R = 0.98) with the tumor fraction calculated from short‐read sequencing of the same samples. cfDNA size profile, fragmentation patterns, fragment‐end composition, and nucleosome profiling near transcription start sites in plasma and urine exhibited the typical cfDNA features. Additionally, a high proportion of long tumor‐derived cfDNA fragments (> 300 bp) are recovered in plasma and urine using ONT sequencing. ONT sequencing is a cost‐effective, fast, and deployable approach for obtaining genomic and fragmentomic results from liquid biopsies, allowing the analysis of previously understudied cfDNA populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pathology, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
- Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.
- Urology, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
- Amsterdam UMC Location University of Amsterdam, Center for Experimental and Molecular Medicine, Laboratory for Experimental Oncology and Radiobiology, Amsterdam, The Netherlands.
- Cancer Center Amsterdam, Gastroenterology Endocrinology Metabolism, Amsterdam, The Netherlands.
- Oncode Institute, Amsterdam, The Netherlands.
ORCID-Profile: Normastuti Adhini Tantyo, Nils Evander, Birgit Mm Wever, Kristiaan J Lenos, Idris Bahce, Jakko A Nieuwenhuijzen, D Michiel Pegtel, Norbert Moldovan, Florent Mouliere
Förderung
- KWF Kankerbestrijding (DCS)
Zitieren
APA
van der Pol, Y., Tantyo, N. A., Evander, N., Hentschel, A. E., Wever, B. M., Ramaker, J., Bootsma, S., Fransen, M. F., Lenos, K. J., Vermeulen, L., Schneiders, F. L., Bahce, I., Nieuwenhuijzen, J. A., Steenbergen, R. D., Pegtel, D. M., Moldovan, N., & Mouliere, F. (2023). Real‐time analysis of the cancer genome and fragmentome from plasma and urine cell‐free DNA using nanopore sequencing. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.202217282
Vancouver
van der Pol Y, Tantyo NA, Evander N, Hentschel AE, Wever BM, Ramaker J, et al. Real‐time analysis of the cancer genome and fragmentome from plasma and urine cell‐free DNA using nanopore sequencing. EMBO Molecular Medicine. 2023. doi:10.15252/emmm.202217282
BibTeX
@article{vanderPol2023,
author = {van der Pol, Ymke and Tantyo, Normastuti Adhini and Evander, Nils and Hentschel, Anouk E and Wever, Birgit Mm and Ramaker, Jip and Bootsma, Sanne and Fransen, Marieke F and Lenos, Kristiaan J and Vermeulen, Louis and Schneiders, Famke L and Bahce, Idris and Nieuwenhuijzen, Jakko A and Steenbergen, Renske Dm and Pegtel, D Michiel and Moldovan, Norbert and Mouliere, Florent},
title = {Real‐time analysis of the cancer genome and fragmentome from plasma and urine cell‐free DNA using nanopore sequencing},
journal = {EMBO Molecular Medicine},
year = {2023},
doi = {10.15252/emmm.202217282}
}
EUVIMED